Solid Biosciences CTO granted 54,925 RSUs
Solid Biosciences Inc. reported that Chief Technology Officer Paul Herzich acquired 54,925 restricted stock units (RSUs) linked to the company’s common stock as part of his equity compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Solid Biosciences Inc. reported that Chief Technology Officer Paul Herzich acquired 54,925 restricted stock units (RSUs) linked to the company’s common stock as part of his equity compensation. These RSUs were earned under performance stock units (PSUs) originally granted on June 11, 2024.
The PSUs vest in four equal 25% tranches upon achieving independent, pre-set performance milestones tied to business objectives. The Board determined the second milestone was met on January 29, 2026, triggering this 54,925-unit award. These shares will actually vest only if Herzich remains in service on the related Evaluation Date, anticipated in the first quarter of 2027.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 54,925 | $0.00 | $0.00 |
Footnotes (2)
- F1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
- F2. Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.
Key Figures
Key Terms
Restricted Stock Units financial
Performance stock units financial
Performance Milestones financial
non-market and non-financial financial
Evaluation Date financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Solid Biosciences (SLDB) report for Paul Herzich?
How many RSUs did the SLDB CTO acquire in this Form 4 filing?
What are the terms of the performance stock units mentioned for Solid Biosciences (SLDB)?
Why did 54,925 RSUs become earned for the SLDB CTO on January 29, 2026?
When will the newly awarded RSUs for Solid Biosciences’ CTO actually vest?
Are the SLDB performance milestones based on stock price or financial metrics?
AI-generated analysis. How Rhea-AI works. Not financial advice.